We provide you with 20 years of free, institutional-grade data for PYPD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PYPD. Explore the full financial landscape of PYPD stock.
| Reported Date | CIK | Ticker | Type |
|---|
PolyPid Ltd(NASDAQ:PYPD) 
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) s...
Website: http://www.polypid.com
Founded: 2008
Full Time Employees: 57
CEO: Amir Weisberg
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about PYPD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.